Abstract: The present invention provides a method for acquiring auxiliary information useful to assist a diagnosis or treatment of prostate cancer. The method for acquiring auxiliary information of the present invention is a method for acquiring auxiliary information to assist a diagnosis or treatment of prostate cancer, and includes a step (C) of dividing a concentration value of a prostate specific antigen having a ?-N-acetylgalactosamine residue at a non-reducing terminal of a sugar chain, contained in a sample derived from a living body, by a volume value of prostate of the living body to calculate the concentration value of the GalNAc-PSA per prostate volume.

Abstract: The present invention provides methods that are for acquiring various types of supplementary information used for diagnosis or treatment of prostate cancer, and that can be implemented in a less-invasive manner at a low cost. Provided are, by measuring the content of prostate specific antigen (PSA) having a ?-N-acetylgalactosamine residue at a non-reducing terminal of a sugar chain in a specimen, and comparing the measured value with a threshold value, (1) a method for estimating whether a Gleason score (primary pattern and secondary pattern) is not less than or less than a prescribed value, (2) a method for estimating whether the pathological stage (pT) is not less than or less than a prescribed value, and (3) a method for acquiring information for assessment indicating diagnosis or treatment should be actively conducted because a GS at gross total removal is expected to be higher than a GS at biopsy.

Abstract: The present invention relates to a method for determining prostate carcinoma, including obtaining a ratio 1 between an amount of a free prostate specific antigen and an amount of a free PSA having an ?(2,3) glycan, the free PSA having an ?(2,3) glycan being a free prostate specific antigen having a glycan in which a terminal sialic acid residue of the glycan is ?(2,3)-linked to a second galactose residue from a terminal of the glycan, in a sample derived from a subject; obtaining a ratio 2 between the ratio 1 and a volume of the prostate of the subject; and determining prostate carcinoma based on the obtained ratio 2.

Abstract: The present invention provides methods that are for acquiring various types of supplementary information used for diagnosis or treatment of prostate cancer, and that can be implemented in a less-invasive manner at a low cost. Provided are, by measuring the content of prostate specific antigen (PSA) having a ?-N-acetylgalactosamine residue at a non-reducing terminal of a sugar chain in a specimen, and comparing the measured value with a threshold value, (1) a method for estimating whether a Gleason score (primary pattern and secondary pattern) is not less than or less than a prescribed value, (2) a method for estimating whether the pathological stage (pT) is not less than or less than a prescribed value, and (3) a method for acquiring information for assessment indicating diagnosis or treatment should be actively conducted because a GS at gross total removal is expected to be higher than a GS at biopsy.

Abstract: The present invention relates to a method for acquiring auxiliary information for diagnosis and treatment (medical care) of prostate cancer. A method for acquiring medical care auxiliary information for estimating a risk of prostate cancer recurrence with a specimen of prostate tissue, wherein an at least three-stage evaluation score is used to express a quantity of biological material in a tumor site of the specimen, the biological material having a ?-N-acetylgalactosamine residue at a nonreducing terminal of a sugar chain.

Abstract: An automatic analyzing apparatus 10 includes a chip rack 11 that stores a pipette chip, a pipette 12 into which a specimen is injected, a conveyance unit that conveys the pipette 12 by parallel translation, a reagent rack 14, a reaction unit 15, a detection unit 16, and a detection block unit 17. The pipette chip stored by the chip rack 11 has a planar structure to directly and optically detect the specimen. The chip rack 11 includes, in a hole that receives the pipette chip, a guide corresponding to the structure of the pipette chip. The pipette 12 sucks or discharges the specimen via the pipette chip mounted onto the tip thereof by a drive of a pump. In the detection unit 16, a measurement is carried out with the pipette chip arranged so that the plane that receives light is vertical to an optical axis.

Abstract: An object of the present invention is to provide a novel Pca determination method and a Pca malignancy determination method. The present invention is an invention relating to a “prostate carcinoma determination method, including determining the ratio of the amount of free prostate specific antigen, which has a glycan in which the terminal sialic acid residue of the glycan is ?(2,3)-linked to a second galactose residue from the terminal of the glycan, to the amount of free PSA in a biological sample, and then determining that prostate carcinoma is developed or the probability of developing prostate carcinoma is high in the case where the ratio is 40% or higher.

Abstract: The method for distinguishing between prostate carcinoma and benign prostatic hyperplasia comprising: bringing an analyte sample containing a prostate-specific antigen (PSA) into contact with a carrier having an anti-free PSA antibody immobilized thereon, thereby binding free PSA to the anti-free PSA antibody immobilized on the carrier; thereafter bringing the carrier in which the free PSA is bound to the immobilized anti-free PSA antibody into contact with a monoclonal antibody capable of specifically recognizing a glycan in which a terminal sialic acid residue is bound to galactose through an ?(2,3) bond, thereby binding the monoclonal antibody recognizing the glycan to the free PSA bound to the anti-free PSA antibody; measuring the amount of the free PSA having an N-type glycan in which a terminal sialic acid residue is bound to galactose through an ?(2,3) bond; comparing the measured amount thus obtained with a preset cutoff value for prostate carcinoma and benign prostatic hyperplasia, thereby determinin

Abstract: An automatic analyzing apparatus 10 includes a chip rack 11 that stores a pipette chip, a pipette 12 into which a specimen is injected, a conveyance unit that conveys the pipette 12 by parallel translation, a reagent rack 14, a reaction unit 15, a detection unit 16, and a detection block unit 17. The pipette chip stored by the chip rack 11 has a planar structure to directly and optically detect the specimen. The chip rack 11 includes, in a hole that receives the pipette chip, a guide corresponding to the structure of the pipette chip. The pipette 12 sucks or discharges the specimen via the pipette chip mounted onto the tip thereof by a drive of a pump. In the detection unit 16, a measurement is carried out with the pipette chip arranged so that the plane that receives light is vertical to an optical axis.

Abstract: An object of the present invention is to provide a method for distinguishing between prostate carcinoma and benign prostatic hyperplasia with high sensitivity and good reproducibility using a small amount of an analyte sample.